Abstract: Prostate-specific membrane antigen (PSMA) targeted compounds having formula (I), nanoclusters formed thereof, pharmaceutical compositions comprising a plurality of these compounds, and methods for treating and detecting cancers in a subject are described herein.

Abstract: A composition for treating a disorder in a subject includes a polyethylene glycolylated (PEGylated) nanoparticle, at least one hydrophobic therapeutic agent coupled to the surface of the nanoparticle; and at least one targeting moiety coupled to polyethylene glycol of the nanoparticle for targeting the composition to a cell associated with disorder.

Abstract: A phthalocyanine compound or targeted conjugate thereof having the formula (I).

Abstract: A composition for treating a disorder in a subject includes a polyethylene glycolylated (PEGylated) nanoparticle, at least one hydrophobic therapeutic agent coupled to the surface of the nanoparticle; and at least one targeting moiety coupled to polyethylene glycol of the nanoparticle for targeting the composition to a cell associated with disorder.

Abstract: A composition for treating a disorder in a subject includes a polyethylene glycolylated (PEGylated) nanoparticle, at least one hydrophobic therapeutic agent coupled to the surface of the nanoparticle; and at least one targeting moiety coupled to polyethylene glycol of the nanoparticle for targeting the composition to a cell associated with disorder.

Abstract: Compounds that are PSMA ligands, pharmaceutical compositions comprising these compounds, methods for treating and detecting cancers in a subject, methods for identifying cancer cells in a sample are described herein.

Abstract: A phthalocyanine compound or targeted conjugate thereof having the formula (I).

Abstract: A phthalocyanine compound or targeted conjugate thereof having the formula (I).

Abstract: Compounds that are PSMA ligands, pharmaceutical compositions comprising these compounds, methods for treating and detecting cancers in a subject, methods for identifying cancer cells in a sample are described herein.

Abstract: Compounds that are PSMA ligands, pharmaceutical compositions comprising these compounds, methods for treating and detecting cancers in a subject, methods for identifying cancer cells in a sample are described herein. Prostate-specific membrane antigen (PSMA) is a 120 kDa protein expressed in prostate tissues and was originally identified by reactivity with a monoclonal antibody designated 7EII-C5 (Horoszewicz et al., 1987, Anticancer Res. 7:927-935; U.S. Pat. No. 5,162,504). PSMA is characterized as a type II transmembrane protein sharing sequence identity with the transferrin receptor (Israeli et al., 1994, Cancer Res. 54:1807-1811).

Abstract: A phthalocyanine compound or targeted conjugate thereof having the formula (I).

Abstract: A composition for treating a disorder in a subject includes a polyethylene glycolylated (PEGylated) nanoparticle, at least one hydrophobic therapeutic agent coupled to the surface of the nanoparticle; and at least one targeting moiety coupled to polyethylene glycol of the nanoparticle for targeting the composition to a cell associated with disorder.

Abstract: A photoelectric stimulating electrode for photoelectric activation of a neuron includes a plurality of semiconductor nanoparticles adapted to be positioned proximate a neuron. The semiconductor nanoparticles upon excitation with light of a first wave length generate an electric field and/or current effective to stimulate the neuron.

Abstract: Binary or ternary nanoparticles containing a group I metal, a group VI non-metal, and perhaps a group III, IV, or V non-metal are produced using a single or multiple source precursor. A precursor and a surfactant are mixed, a solvent is added to the mixture, the mixture is heated at a temperature close to the boiling point of the solvent for a desired amount of time, and the mixture is cooled. The nanoparticles are separated from the solvent by permitting the solvent to evaporate. The resulting nanoparticles may be used in photovoltaic and other semiconductor applications, imaging, biological applications, or in compositions.

Abstract: Metal oxide nanoparticles are described that contain a non-metallic dopant selected from the group consisting of boron, carbon, silicon, germanium, nitrogen, phosphorous, arsenic, sulfur, selenium, tellurium, fluorine, chlorine, bromine, iodine, and combinations thereof. Methods of making and using these doped metal oxide nanoparticles are also described.